NCT06745895 Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
| NCT ID | NCT06745895 |
| Status | Recruiting |
| Phase | — |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Condition | Colorectal Cancer Screening |
| Study Type | INTERVENTIONAL |
| Enrollment | 350 participants |
| Start Date | 2024-10-21 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 350 participants in total. It began in 2024-10-21 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC screening among FQHC patients ages 45-75.
Eligibility Criteria
Inclusion Criteria: * Participants must be receiving care at one of the participating FQHC clinics. * Participants must be 45-75 years of age. * Participants must not be up to date with Colorectal Cancer (CRC) screening recommendations such as no colonoscopy in the past 10 years, occult blood test in the past 12 months. * Participants must never have had Hepatitis C Virus (HCV) antibody screening. * Participants must be able to read, write, and understand English or Spanish. * Participants must have no personal history of CRC or current presumptive CRC symptoms such as unresolved rectal bleeding or abdominal pain/bloating. * Participants must be at average risk for CRC (no hereditary CRC syndromes such as lower gastrointestinal (GI) bleeding, persistent diarrhea, bloating, or lower GI pain, no strong family history of CRC). * Participants must be asymptomatic for HCV. * Participants receiving intervention materials must be able and willing to complete surveys and receive the patient level intervention. * Participants completing qualitative interviews must be willing to complete a remote interview via phone or teleconference software such as ZOOM. * Participants completing qualitative interviews must be willing to be audio recorded. * Participants recruited for qualitative interviews only (did not receive MATCHES intervention materials) must have a clinic visit within prior two months. * All Participants must be able to provide informed consent. Exclusion Criteria: * Participants that do not meet all Inclusion Eligibility requirements will be excluded.
Contact & Investigator
Shannon Christy, PhD
PRINCIPAL INVESTIGATOR
Moffitt Cancer Center
Frequently Asked Questions
Who can join the NCT06745895 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Colorectal Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06745895 currently recruiting?
Yes, NCT06745895 is actively recruiting participants. Contact the research team at Carol.Boxtha@Moffitt.org for enrollment information.
Where is the NCT06745895 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT06745895 clinical trial?
NCT06745895 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Shannon Christy, PhD at Moffitt Cancer Center. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.